BIOVENTIX Archives - Som2ny Network

0

Maynard Paton | BIOVENTIX: H1 2025 Revenue Up Just 1% Due To ‘Mature’ Markets Leaves £24 Shares Yielding 6%-Plus And Future Growth Seemingly Dependent On Promising Alzheimer’s R&D And Associated Royalty/Supply Arrangements

Apologies! This BVXP H1 2025 review has taken somewhat longer than expected to produce. BVXP’s FY 2025 results are due tomorrow (27 October) and to ...

admin December 14, 2025

Maynard Paton | BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix

22 October 2024By Maynard Paton H1 2024 results summary for Bioventix (BVXP): A record H1, showing revenue up 13%, profit up 15% and the ...

admin May 29, 2025

Maynard Paton | BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%

04 March 2025By Maynard Paton FY 2024 results summary for Bioventix (BVXP): A record FY, showing revenue up 6% and profit up 5%, although the 3p ...

admin March 14, 2025

Maynard Paton | BIOVENTIX: H1 2025 Revenue Up Just 1% Due To ‘Mature’ Markets Leaves £24 Shares Yielding 6%-Plus And Future Growth Seemingly Dependent On Promising Alzheimer’s R&D And Associated Royalty/Supply Arrangements

Maynard Paton | BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix

Maynard Paton | BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%

Compare items

Shopping cart